Gold prices cool after hitting over 2-week high on Fed independence fears
Jonathan Rubin, the Senior Vice President and Chief Medical (TASE:BLWV) Officer of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a $1.8 billion market cap pharmaceutical company with impressive 89% gross profit margins, executed a series of transactions involving the company’s common stock. On February 21, Rubin sold 927 shares at a price of $39.15 each, totaling $36,292. Following this transaction, Rubin’s direct ownership in the company amounted to 7,853 shares. According to InvestingPro analysis, the company maintains strong financial health with a "GREAT" overall rating.
In addition to the sale, Rubin engaged in multiple acquisition transactions between February 21 and February 23. These transactions included the acquisition of 1,875 shares through the settlement of performance share units and additional shares acquired through restricted stock units. These acquisitions were reported at no cost to Rubin. The stock has recently experienced a significant 17% decline over the past week, trading at $32.68. InvestingPro subscribers can access 12 additional key insights about SUPN’s valuation and future prospects.
The transactions reflect Rubin’s ongoing involvement with Supernus Pharmaceuticals, a company based in Rockville, Maryland, known for its pharmaceutical preparations. For comprehensive insider trading analysis and detailed financial metrics, investors can access the full Pro Research Report available on InvestingPro.
In other recent news, Supernus Pharmaceuticals has been in the spotlight due to several significant developments. The company recently announced disappointing results from its Phase 2b study for SPN-820, intended for treatment-resistant depression, as it failed to meet its primary endpoint. This has led to a downgrade by Cantor Fitzgerald, with analyst Kristen Kluska reducing the stock rating from Overweight to Neutral and lowering the price target to $36 from $57. Concurrently, Stifel maintained a Hold rating on Supernus, with a price target of $38, highlighting the FDA approval of ONAPGO, a new treatment for Parkinson’s disease.
TD Cowen also adjusted its outlook, raising the price target for Supernus to $44 following the approval of ONAPGO, expected to launch in the second quarter of 2025. The approval is seen as a significant addition to Supernus’ Parkinson’s disease portfolio, with potential peak sales estimated at $200 million. Despite the challenges with SPN-820, Supernus continues to focus on its core products, with Qelbree noted as a primary growth driver. Analysts have expressed optimism about Qelbree’s market performance, particularly in treating ADHD. These developments reflect Supernus’ ongoing efforts to expand its therapeutic offerings and strengthen its position in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.